The annual masterclass, organised by the Saudi Oncology Society (SOS), addressed the knowledge gaps in breast cancer care in Saudi Arabia via a virtual multidisciplinary educational exchange platform. Presentations focussed on the detection, diagnosis, and management of breast cancer, as well as clinical trial analysis. Prof Meteb Al-Foheidi discussed the subgroup analysis of the Phase III MONARCH 2 trial specifically, in which the efficacy of abemaciclib plus fulvestrant as first- and second-line therapy for HR+, HER2-negative advanced breast cancer was assessed.
Latest articlesAll articles
Multidisciplinary Team Approach in Cancer Care: A Review of The Latest Advancements
The management of patients with cancer is complex and requires contribution from a range of healthcare professionals working alongside specialist oncology consultants to address patients’ needs and optimise outcomes.
Editor’s Pick: More than FOLFOX and FOLFIRI: The Management of Metastatic Colorectal Cancer in the Era of Precision Oncology
Colorectal cancer (CRC) is the second most common cause of cancer-related death in the USA. Despite improvements in screening rates and in the overall survival (OS) of patients with localised and advanced disease over the past few decades, the 5-year OS of patients with metastatic disease is still extremely poor and estimated to be approximately 15%.
Perspectives on Hepatic Metastases and the Minimally Invasive Approach to Resection
The liver is the most common site for colorectal cancer (CRC) metastases, accounting for 80% of patients with Stage IV CRC and 40% as the only site of distant disease. Of the patients with CRC, 20–25% present with synchronous metastases and 50–60% will develop metachronous disease. Liver metastases develop in the absence of lymph node involvement and, presumably, this occurs via the haematogenous route (the portal circulation) in gastrointestinal tumours from where tumour cells can embolise via the mesenteric veins.